来自MSN12 天
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu ...
Investopedia12 天
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.
biopharma-reporter11 天
FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient. The U.S.
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?
Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX ...
This Is The One Reason Moderna, Novavax, And Drug Stocks Slumped
Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect <a target=_blank ...
KSL11 天
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...